GWPH News and Press, GW Pharmaceuticals Plc From 06/30/20

GW Pharmaceuticals (NASDAQ: GWPH ) announces strategy for bringing its pipeline product nabiximols to the U.S. market. More news on: GW Pharmaceuticals plc, Healthcare stocks news, Read more ...

 - Potential accelerated pathway to NDA submission -  - Clinical program of five Phase 3 trials provides multiple options for NDA submission, as early as 2021 - - Webcast featuring a range of guest speakers to be held today from 10:00am-12:00pm EDT - CARLSBAD, Calif., June 30, ...

Almost two years ago, the U.S. Food and Drug Administration (FDA) approved the first-ever cannabinoid-derived drug, created by GW Pharmaceuticals (NASDAQ: GWPH) . The drug is called Epidolex and is used to treat patients with severe drug-resistant seizures that begin during childhood. Since ...

Zogenix Buoyant on FDA Approval for Fintepla Zogenix ( ZGNX ) reported that the FDA has approved its Fintepla drug for treating seizures associated with Dravet syndrome. The drug may now be used for treating patients 2 years of age and older. It will be distributed under the FINTEPLA R...

GW Pharmaceuticals (NASDAQ: GWPH) and  Cara Therapeutics (NASDAQ: CARA) often get lumped together as cannabinoid-focused biotechs. However, that label is really only applicable to GW Pharmaceuticals. Although Cara Therapeutics has done some preclinical testing on a cannabinoid recept...

Zogenix ( ZGNX -3.7% ) has experienced substantial volatility today after the FDA announced approval of Fintepla (fenfluramine) for a rare type of epilepsy called Dravet syndrome after the close yesterday, normally a bullish event despite broad market behavior. More news on: Zogenix, I...

Zogenix (NASDAQ: ZGNX ) says the Food and Drug Administration approved its Fintepla drug to treat seizures associated with Dravet syndrome, a rare form of childhood epilepsy. More news on: Zogenix, Inc., GW Pharmaceuticals plc, Healthcare stocks news, Read more ...

GW Pharmaceuticals plc (Nasdaq: GWPH) said that the UK Home Office has reclassified Epidiolex, the company’s cannabidiol medicine as a Schedule 5 drug. The company said that the change will take effect immediately in all four of the constituent nations of the UK – with Northern...

GW’s cannabis-based medicine rescheduled following approval by the European Medicines Agency (EMA) and an independent assessment by the Advisory Council on the Misuse of Drugs (ACMD) Burden on patients, their families and healthcare professionals eased due to the reduction in c...

There's a growing movement for marijuana legalization in the U.S. and around the world. And a key part in winning regulators over is in showing them that the industry can be trusted to govern itself. However, the problem for the industry is that there's too much excitement surrounding its grow...